SCHEMBL5656443

SCHEMBL5656443

COc1cccc(N2C(=O)C(c3cc(C)c(O)c(C)c3)(c3cc(C)c(O)c(C)c3)c3ccccc32)c1

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.44
MGLL Q99685 1/20 0.43
ALDH1A1 P00352 5/20 0.40
SCN9A Q15858 1/20 0.40
KDM4E B2RXH2 1/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
CYP1A2 P05177 1/20 0.38
KMT2A Q03164 2/20 0.37
MEN1 O00255 1/20 0.37
GAA P10253 1/20 0.37
GFER P55789 1/20 0.37
CNR1 P21554 1/20 0.37
GPR55 Q9Y2T6 1/20 0.37
CBX7 O95931 1/20 0.36
CDYL2 Q8N8U2 1/20 0.36
CDYL Q9Y232 1/20 0.36
CDY1; CDY1B Q9Y6F8 1/20 0.36
RAB9A P51151 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5662112 0.97 MAPT (0.41) MAPTMGLLALDH1A1SCN9AKDM4E
SCHEMBL5661100 0.96 MAPT (0.41) MAPTMGLLALDH1A1SCN9AKDM4E
SCHEMBL5656731 0.96 MAPT (0.41) MAPTMGLLALDH1A1SCN9AKDM4E
SCHEMBL5658510 0.95 CNR1 (0.46) MAPTMGLLALDH1A1SCN9AKDM4E
SCHEMBL5658916 0.95 MAPT (0.40) MAPTMGLLALDH1A1SCN9AKDM4E
SCHEMBL5659434 0.94 MAPT (0.42) MAPTMGLLALDH1A1SCN9AKDM4E
SCHEMBL5661921 0.94 MAPT (0.41) MAPTMGLLALDH1A1SCN9AKDM4E
SCHEMBL5660840 0.92 MAPT (0.38) MAPTMGLLALDH1A1SCN9AKDM4E
SCHEMBL5658260 0.92 ALDH1A1 (0.40) MAPTMGLLALDH1A1SCN9AKDM4E
SCHEMBL5657669 0.91 MAPT (0.39) MAPTMGLLALDH1A1SCN9AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7250442-B2 Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators ELI LILLY AND COMPANY (US) 2007-07-31 US claimed
US-7250442-B2 Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators ELI LILLY AND COMPANY (US) 2007-07-31 US disclosed
US-7250442-B2 Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators ELI LILLY AND COMPANY (US) 2007-07-31 US disclosed
US-7250442-B2 Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators ELI LILLY AND COMPANY (US) 2007-07-31 US disclosed
US-20050054712-A1 Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators ELI LILLY AND COMPANY 2005-03-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050054712-A1 Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators NR3C2, NR5A1, NR5A2 MAPT 3588/4885MGLL 3012/4885ALDH1A1 723/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.